Treatment for COVID-19—a cohort study from Northern Italy

Multicentre, retrospective cohort study with multivariable Cox proportional-hazards modelling and survival-time inverse-probability-weighting, evaluating the impact of different treatments on survival of proven COVID-19 patients admitted to two Hospitals in the province of Piacenza, Italy. Use of to...

Descripción completa

Detalles Bibliográficos
Autores principales: Guglielmetti, Lorenzo, Aschieri, Daniela, Kontsevaya, Irina, Calabrese, Francesco, Donisi, Alessandra, Faggi, Alberto, Ferrante, Patrizia, Fronti, Elisa, Gerna, Laura, Leoni, Maria Cristina, Paolillo, Franco, Ratti, Giovanna, Ruggieri, Alessandro, Sacchini, Daria, Scotti, Marta, Valdatta, Caterina, Stabile, Marco, Taliani, Gloria, Codeluppi, Mauro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8545945/
https://www.ncbi.nlm.nih.gov/pubmed/34697322
http://dx.doi.org/10.1038/s41598-021-00243-4
Descripción
Sumario:Multicentre, retrospective cohort study with multivariable Cox proportional-hazards modelling and survival-time inverse-probability-weighting, evaluating the impact of different treatments on survival of proven COVID-19 patients admitted to two Hospitals in the province of Piacenza, Italy. Use of tocilizumab and of high doses of low molecular weight heparin, but not of antivirals (either alone or in combination), azithromycin, and any corticosteroid, was independently associated with lower mortality. Our results support further clinical evaluation of high doses of low molecular weight heparin and tocilizumab as COVID-19 therapeutics.

Ejemplares similares